Understanding aggressive prostate cancer in high-risk and African American men
Official title: Project #1
Funded at Howard University · NIH-11196094 · Data updated 2026-11-12
This project will analyze tumor and genetic differences in metastatic prostate cancer to help high-risk men—especially African American men—get better prognoses and more tailored care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Howard University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $228,920 |
| NIH project number | 5U54CA295337-02 |
| Project ID | NIH-11196094 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with locally metastatic prostate cancer who can provide tumor tissue and clinical data, with outreach focused on high-risk and African American patients.
✕Less likely to help
Men with only early-stage localized prostate cancer who cannot provide metastatic tissue or clinical follow-up data may not directly benefit from this project.
What this research studies
Researchers at Howard University and Johns Hopkins will build a cohort of men with locally metastatic prostate cancer, prioritizing high-risk and African American patients, and collect tumor samples and clinical information. They will perform genomic and epigenomic profiling and use tissue-based assays to measure tumor and immune microenvironment features. The team will compare primary and metastatic tumors and link molecular patterns to clinical outcomes and genetic ancestry. Findings aim to identify biomarkers that signal aggressive, lethal disease and could guide future personalized treatments.
Why it matters
Potential benefit: If successful, this work could identify biomarkers that better predict which prostate cancers are likely to be deadly and point to more personalized treatment or monitoring for high-risk men.
How similar studies have gone: Previous research has shown ancestry-linked genomic and immune differences in prostate tumors, but translating those findings into reliable clinical biomarkers remains largely unproven.
Where this research is happening
-
Howard University
Washington, United States Active
Researchers
- Principal investigator: Hudson, Tamaro Syton — Howard University
- Study coordinator: Hudson, Tamaro Syton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.